Compare Moderna, Inc. (MRNA) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Tripadvisor Inc Common Stock — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Tripadvisor Inc Common Stock trades at $13.82 (market cap $1.68B). The key difference: Moderna, Inc. is far larger — about 14× Tripadvisor Inc Common Stock's market cap, and Moderna, Inc. is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| MRNA | TRIP | |
|---|---|---|
Market Cap | $23.60B | $1.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $81.80 | $19.14 |
52-Week Low | $22.36 | $9.24 |
Enterprise Value | $19.70B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Tripadvisor (TRIP) trades at $13.8, down 5.35% over 24 hours. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators are neutral. Fundamentally, revenue grew to $1.89B in 2025 with a net income margin of 0.99%, but recent earnings misses and a high P/E of 131.09 raise valuation concerns. The recent $700M sale of TheFork to American Express simplifies the business and provides a cash infusion.
Outlook is mixed: the sale of TheFork and focus on core experiences offer strategic clarity, but stiff competition and macroeconomic pressures pose risks. Analyst consensus is a 'Hold' with a $13.87 price target, slightly above the current price, indicating limited near-term upside amid cautious sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
